Cargando…

Adverse events after pleurodesis in patients with malignant pleural effusion

BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Terra, Ricardo Mingarini, da Costa, Priscila Berenice, Dela Vega, Alberto Jorge Monteiro, Pêgo-Fernandes, Paulo Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399432/
https://www.ncbi.nlm.nih.gov/pubmed/32802429
http://dx.doi.org/10.21037/jtd-19-3850
_version_ 1783566147756490752
author Terra, Ricardo Mingarini
da Costa, Priscila Berenice
Dela Vega, Alberto Jorge Monteiro
Pêgo-Fernandes, Paulo Manuel
author_facet Terra, Ricardo Mingarini
da Costa, Priscila Berenice
Dela Vega, Alberto Jorge Monteiro
Pêgo-Fernandes, Paulo Manuel
author_sort Terra, Ricardo Mingarini
collection PubMed
description BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective analysis of patients submitted to pleurodesis (2009–2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2(nd), 5(th) and 10(th) days after. RESULTS: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5(th) day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. CONCLUSIONS: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher.
format Online
Article
Text
id pubmed-7399432
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73994322020-08-13 Adverse events after pleurodesis in patients with malignant pleural effusion Terra, Ricardo Mingarini da Costa, Priscila Berenice Dela Vega, Alberto Jorge Monteiro Pêgo-Fernandes, Paulo Manuel J Thorac Dis Original Article BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective analysis of patients submitted to pleurodesis (2009–2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2(nd), 5(th) and 10(th) days after. RESULTS: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5(th) day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. CONCLUSIONS: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher. AME Publishing Company 2020-07 /pmc/articles/PMC7399432/ /pubmed/32802429 http://dx.doi.org/10.21037/jtd-19-3850 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Terra, Ricardo Mingarini
da Costa, Priscila Berenice
Dela Vega, Alberto Jorge Monteiro
Pêgo-Fernandes, Paulo Manuel
Adverse events after pleurodesis in patients with malignant pleural effusion
title Adverse events after pleurodesis in patients with malignant pleural effusion
title_full Adverse events after pleurodesis in patients with malignant pleural effusion
title_fullStr Adverse events after pleurodesis in patients with malignant pleural effusion
title_full_unstemmed Adverse events after pleurodesis in patients with malignant pleural effusion
title_short Adverse events after pleurodesis in patients with malignant pleural effusion
title_sort adverse events after pleurodesis in patients with malignant pleural effusion
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399432/
https://www.ncbi.nlm.nih.gov/pubmed/32802429
http://dx.doi.org/10.21037/jtd-19-3850
work_keys_str_mv AT terraricardomingarini adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion
AT dacostapriscilaberenice adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion
AT delavegaalbertojorgemonteiro adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion
AT pegofernandespaulomanuel adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion